Syndax Pharmaceuticals stock gains on investor conference schedule and steady September trading

Published on 09/17/2026 at 18:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Syndax Pharmaceuticals stock traded around USD 17.92 on September 17, 2026, keeping a moderate distance from its 52-week high after a recent session gain. The company also highlighted two September investor conference appearances in New York, adding visibility for its pipeline story.

SNDX, US88906L1052, Illustration mit AI erstellt.

Syndax Pharmaceuticals stock (ISIN US88906L1052) traded at USD 17.92 on Nasdaq as of September 17, 2026, leaving the shares roughly 30 percent below their 52-week high of USD 25.59 and modestly above the recent low of USD 12.99 per data from a US trading portal on that date.

Investor conferences put Syndax in the spotlight

According to StockTitan in a release dated September 1, 2026, Syndax Pharmaceuticals announced that Chief Executive Officer Michael A. Metzger and members of the management team will participate in two investor conferences in New York in September 2026.

The company plans a fireside chat at the Citi 2026 Biopharma Back to School Conference on September 10, 2026, at 8:40 a.m. ET and another at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 10:00 a.m. ET, with live webcasts available via the investor section of its website, as detailed by StockTitan.

Recent trading and volatility in SNDX stock

Per a US brokerage overview, Syndax Pharmaceuticals stock changed hands between USD 17.37 and USD 18.05 on Nasdaq on September 17, 2026, closing at USD 17.92 with trading volume of about 542,750 shares compared with an average volume of roughly 1.53 million shares.

That reference portal also shows a 52-week range from a low of USD 12.99 to a high of USD 25.59 for SNDX as of September 17, 2026, implying that the stock is currently around 38 percent above its 52-week low while still about 30 percent below the 52-week peak, a spread that underscores the volatility investors have experienced over the past year.

Analyst expectations and technical sentiment

A technical snapshot from a major charting platform on September 16, 2026, cited a short-term technical rating of “sell” on Syndax Pharmaceuticals, Inc., with aggregated analyst estimates pointing to a maximum price target of USD 56.00 and a minimum target of USD 19.00 for SNDX, according to TradingView.

This range of analyst targets implies a potential upside of about 213 percent to the high estimate and around 6 percent to the low estimate from the USD 17.92 trading level on September 17, 2026, illustrating how divided expectations are on the stock’s medium-term trajectory.

SNDX stock price and market metrics

On Nasdaq, Syndax Pharmaceuticals stock was quoted at USD 17.92 on September 17, 2026, with an intraday range between USD 17.37 and USD 18.05 and volume of roughly 542,750 shares; the company’s market capitalization stood near USD 1.6 billion in USD terms as of that date based on the same portal’s data.